Alentis Therapeutics
Treating cancer and reversing fibrosis
Basel, Switzerland · Founded 2019 · $172.0M raised
- Headquarters
- Basel
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- alentis.ch
- Total Funding
- $172.0M
- Last Round
- $105.0M Series CApr 2023
- Rounds
- 2
About
Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting Claudin-1 (CLDN1), a protein that plays a key role in solid tumors and organ fibrosis. Founded in 2019 by Professor Thomas Baumert following more than 15 years of pioneering research at the University of Strasbourg and Inserm, Alentis is advancing a pipeline of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) designed to selectively bind exposed CLDN1 in tumor and fibrotic tissue. The company's lead programs, ALE.P02 and ALE.P03, are ADCs in clinical development for CLDN1-positive solid tumors, and ALE.F02 (Lixudebart) targets multi-organ fibrosis. Alentis has received FDA Fast Track designation for ALE.P02 and raised $181.4 million in a Series D financing co-led by Novo Holdings to advance its clinical pipeline.
Summary
Alentis Therapeutics is a Biotech company based in Basel, Switzerland, founded in 2019. It has raised $172.0M in total across 2 rounds, most recently a $105.0M Series C round in Apr 2023.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...